Quanterix (QTRX) Marks Key Milestones in Alzheimer's Testing Advancements
Related Stocks: QTRX
Read the full articleYou might also wanna read
Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release
Truist upgrades Biogen (BIIB) stock to Buy with $235 target ahead of Alzheimer's drug data. Shares rise 1.3% premarket on positive analyst o
Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances
longevity.technology/news/retro-b...
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volun
Beckman Coulter grows Alzheimer’s dx portfolio with CE mark for new assay
Diagnostics specialist Beckman Coulter expanded its portfolio of Alzheimer’s disease diagnostics by earning a CE mark in Europe for its Acce
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engager
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
Comments
Sign in to join the conversation.
No comments yet. Be the first.